NRNP 6635 FINAL EXAM LATEST 2026/2027 |
Psychopathology and Diagnostic Reasoning | Already
Graded A | Walden University | Pass Guaranteed - A+ Graded
Section 1: Neurobiology, Genetics, & Psychopharmacology
Foundations (Q1-18)
Q1: A 28-year-old patient with schizophrenia is prescribed risperidone. The PMHNP
explains that risperidone's therapeutic effect primarily results from antagonism of which
dopamine pathway?
A. Mesocortical pathway—improving positive symptoms through prefrontal cortex
modulation
B. Mesolimbic pathway—reducing positive symptoms through ventral tegmental area to
nucleus accumbens blockade
C. Nigrostriatal pathway—preventing extrapyramidal symptoms through striatal
dopamine enhancement
D. Tuberoinfundibular pathway—increasing prolactin through pituitary dopamine
stimulation
Correct Answer: B
B. Mesolimbic pathway—reducing positive symptoms through ventral tegmental area to
nucleus accumbens blockade [CORRECT]
Rationale: Atypical antipsychotics like risperidone block D2 receptors in the mesolimbic
pathway, reducing hyperdopaminergic activity responsible for positive symptoms
(hallucinations, delusions). A is incorrect because mesocortical hypodopaminergia
relates to negative symptoms, not positive. C is incorrect because nigrostriatal blockade
causes EPS, not prevents it. D is incorrect because tuberoinfundibular blockade
increases prolactin (side effect), not a therapeutic mechanism.
,Q2: A PMHNP is evaluating a patient with treatment-resistant depression.
Pharmacogenomic testing reveals the patient is a CYP2D6 poor metabolizer. Which
antidepressant would require the most significant dose reduction to avoid toxicity?
A. Sertraline
B. Venlafaxine
C. Fluoxetine
D. Bupropion
Correct Answer: C
C. Fluoxetine [CORRECT]
Rationale: Fluoxetine is primarily metabolized by CYP2D6; poor metabolizers
accumulate parent drug and active metabolite norfluoxetine, increasing risk of serotonin
syndrome and QT prolongation. A (sertraline) uses multiple CYP pathways. B
(venlafaxine) is metabolized by CYP2D6 but has active metabolite with different profile.
D (bupropion) is metabolized by CYP2B6, not 2D6.
Q3: The BDNF Val66Met polymorphism has been most consistently associated with:
A. Increased risk of schizophrenia through dopamine receptor dysregulation
B. Reduced activity-dependent BDNF secretion and increased vulnerability to
stress-related depression
C. Enhanced serotonin reuptake transporter function and anxiety resilience
D. Altered GABA receptor subunit composition and panic disorder
Correct Answer: B
B. Reduced activity-dependent BDNF secretion and increased vulnerability to
stress-related depression [CORRECT]
Rationale: The Met allele impairs activity-dependent BDNF release from synaptic
vesicles, reducing neuroplasticity and increasing depression risk, particularly with
childhood adversity. A describes COMT or DISC1 associations. C describes SLC6A4
(serotonin transporter) polymorphisms. D describes GABAergic mechanisms unrelated
to BDNF.
,Q4: A patient on chronic haloperidol develops tardive dyskinesia. The PMHNP
understands this results from:
A. Up-regulation of D2 receptors in the nigrostriatal pathway due to chronic antagonism
B. Down-regulation of D2 receptors in the mesolimbic pathway causing dopamine
supersensitivity
C. Destruction of GABAergic interneurons in the striatum
D. Up-regulation of muscarinic receptors in the tuberoinfundibular pathway
Correct Answer: A
A. Up-regulation of D2 receptors in the nigrostriatal pathway due to chronic antagonism
[CORRECT]
Rationale: Chronic D2 antagonism causes compensatory up-regulation
(supersensitivity) of postsynaptic D2 receptors in the nigrostriatal pathway, leading to
tardive dyskinesia when drug is withdrawn or at end-of-dose intervals. B describes
mesolimbic changes related to psychosis relapse, not TD. C describes Huntington's
mechanism. D is incorrect—TD is dopaminergic, not cholinergic.
Q5: The SLC6A4 gene (serotonin transporter) 5-HTTLPR short allele has been
associated with:
A. Increased serotonin transporter expression and reduced depression risk
B. Decreased serotonin transporter expression and increased stress sensitivity
C. Altered dopamine D2 receptor density and impulsivity
D. Enhanced norepinephrine reuptake and anxiety resilience
Correct Answer: B
B. Decreased serotonin transporter expression and increased stress sensitivity
[CORRECT]
Rationale: The short (S) allele reduces 5-HTT expression and function, leading to less
efficient serotonin reuptake, synaptic serotonin accumulation, and increased amygdala
reactivity to stress—creating a gene × environment interaction for depression. A
describes the long (L) allele. C and D describe unrelated neurotransmitter systems.
, Q6: A PMHNP prescribes aripiprazole for a patient with bipolar disorder. The unique
pharmacodynamic profile of aripiprazole is best described as:
A. Pure D2 antagonist with high affinity for all dopamine receptors
B. D2 partial agonist with functional antagonism at hyperdopaminergic synapses and
agonism at hypodopaminergic synapses
C. Pure 5-HT2A antagonist with no dopamine receptor activity
D. D1 full agonist with D3/D4 antagonism
Correct Answer: B
B. D2 partial agonist with functional antagonism at hyperdopaminergic synapses and
agonism at hypodopaminergic synapses [CORRECT]
Rationale: Aripiprazole's partial agonism (intrinsic activity ~25%) stabilizes dopamine
transmission—antagonizing when dopamine is high (mesolimbic) and agonizing when
low (mesocortical). A describes typical antipsychotics. C describes pure 5-HT2A
antagonists (e.g., mirtazapine). D is pharmacologically incorrect.
Q7: A patient with Parkinson's disease develops visual hallucinations. The PMHNP
recognizes this most likely results from:
A. Excessive dopaminergic medication causing mesolimbic pathway hyperactivity
B. Lewy body pathology directly affecting the visual cortex
C. Anticholinergic medication toxicity
D. Progressive supranuclear palsy misdiagnosis
Correct Answer: A
A. Excessive dopaminergic medication causing mesolimbic pathway hyperactivity
[CORRECT]
Rationale: Dopaminergic medications (levodopa, dopamine agonists) can overstimulate
mesolimbic pathways, producing hallucinations and psychosis—distinguishable from
dementia with Lewy bodies hallucinations by temporal relationship to medication. B
describes DLB mechanism but not medication-induced. C causes delirium, not isolated
hallucinations. D is unrelated.
Psychopathology and Diagnostic Reasoning | Already
Graded A | Walden University | Pass Guaranteed - A+ Graded
Section 1: Neurobiology, Genetics, & Psychopharmacology
Foundations (Q1-18)
Q1: A 28-year-old patient with schizophrenia is prescribed risperidone. The PMHNP
explains that risperidone's therapeutic effect primarily results from antagonism of which
dopamine pathway?
A. Mesocortical pathway—improving positive symptoms through prefrontal cortex
modulation
B. Mesolimbic pathway—reducing positive symptoms through ventral tegmental area to
nucleus accumbens blockade
C. Nigrostriatal pathway—preventing extrapyramidal symptoms through striatal
dopamine enhancement
D. Tuberoinfundibular pathway—increasing prolactin through pituitary dopamine
stimulation
Correct Answer: B
B. Mesolimbic pathway—reducing positive symptoms through ventral tegmental area to
nucleus accumbens blockade [CORRECT]
Rationale: Atypical antipsychotics like risperidone block D2 receptors in the mesolimbic
pathway, reducing hyperdopaminergic activity responsible for positive symptoms
(hallucinations, delusions). A is incorrect because mesocortical hypodopaminergia
relates to negative symptoms, not positive. C is incorrect because nigrostriatal blockade
causes EPS, not prevents it. D is incorrect because tuberoinfundibular blockade
increases prolactin (side effect), not a therapeutic mechanism.
,Q2: A PMHNP is evaluating a patient with treatment-resistant depression.
Pharmacogenomic testing reveals the patient is a CYP2D6 poor metabolizer. Which
antidepressant would require the most significant dose reduction to avoid toxicity?
A. Sertraline
B. Venlafaxine
C. Fluoxetine
D. Bupropion
Correct Answer: C
C. Fluoxetine [CORRECT]
Rationale: Fluoxetine is primarily metabolized by CYP2D6; poor metabolizers
accumulate parent drug and active metabolite norfluoxetine, increasing risk of serotonin
syndrome and QT prolongation. A (sertraline) uses multiple CYP pathways. B
(venlafaxine) is metabolized by CYP2D6 but has active metabolite with different profile.
D (bupropion) is metabolized by CYP2B6, not 2D6.
Q3: The BDNF Val66Met polymorphism has been most consistently associated with:
A. Increased risk of schizophrenia through dopamine receptor dysregulation
B. Reduced activity-dependent BDNF secretion and increased vulnerability to
stress-related depression
C. Enhanced serotonin reuptake transporter function and anxiety resilience
D. Altered GABA receptor subunit composition and panic disorder
Correct Answer: B
B. Reduced activity-dependent BDNF secretion and increased vulnerability to
stress-related depression [CORRECT]
Rationale: The Met allele impairs activity-dependent BDNF release from synaptic
vesicles, reducing neuroplasticity and increasing depression risk, particularly with
childhood adversity. A describes COMT or DISC1 associations. C describes SLC6A4
(serotonin transporter) polymorphisms. D describes GABAergic mechanisms unrelated
to BDNF.
,Q4: A patient on chronic haloperidol develops tardive dyskinesia. The PMHNP
understands this results from:
A. Up-regulation of D2 receptors in the nigrostriatal pathway due to chronic antagonism
B. Down-regulation of D2 receptors in the mesolimbic pathway causing dopamine
supersensitivity
C. Destruction of GABAergic interneurons in the striatum
D. Up-regulation of muscarinic receptors in the tuberoinfundibular pathway
Correct Answer: A
A. Up-regulation of D2 receptors in the nigrostriatal pathway due to chronic antagonism
[CORRECT]
Rationale: Chronic D2 antagonism causes compensatory up-regulation
(supersensitivity) of postsynaptic D2 receptors in the nigrostriatal pathway, leading to
tardive dyskinesia when drug is withdrawn or at end-of-dose intervals. B describes
mesolimbic changes related to psychosis relapse, not TD. C describes Huntington's
mechanism. D is incorrect—TD is dopaminergic, not cholinergic.
Q5: The SLC6A4 gene (serotonin transporter) 5-HTTLPR short allele has been
associated with:
A. Increased serotonin transporter expression and reduced depression risk
B. Decreased serotonin transporter expression and increased stress sensitivity
C. Altered dopamine D2 receptor density and impulsivity
D. Enhanced norepinephrine reuptake and anxiety resilience
Correct Answer: B
B. Decreased serotonin transporter expression and increased stress sensitivity
[CORRECT]
Rationale: The short (S) allele reduces 5-HTT expression and function, leading to less
efficient serotonin reuptake, synaptic serotonin accumulation, and increased amygdala
reactivity to stress—creating a gene × environment interaction for depression. A
describes the long (L) allele. C and D describe unrelated neurotransmitter systems.
, Q6: A PMHNP prescribes aripiprazole for a patient with bipolar disorder. The unique
pharmacodynamic profile of aripiprazole is best described as:
A. Pure D2 antagonist with high affinity for all dopamine receptors
B. D2 partial agonist with functional antagonism at hyperdopaminergic synapses and
agonism at hypodopaminergic synapses
C. Pure 5-HT2A antagonist with no dopamine receptor activity
D. D1 full agonist with D3/D4 antagonism
Correct Answer: B
B. D2 partial agonist with functional antagonism at hyperdopaminergic synapses and
agonism at hypodopaminergic synapses [CORRECT]
Rationale: Aripiprazole's partial agonism (intrinsic activity ~25%) stabilizes dopamine
transmission—antagonizing when dopamine is high (mesolimbic) and agonizing when
low (mesocortical). A describes typical antipsychotics. C describes pure 5-HT2A
antagonists (e.g., mirtazapine). D is pharmacologically incorrect.
Q7: A patient with Parkinson's disease develops visual hallucinations. The PMHNP
recognizes this most likely results from:
A. Excessive dopaminergic medication causing mesolimbic pathway hyperactivity
B. Lewy body pathology directly affecting the visual cortex
C. Anticholinergic medication toxicity
D. Progressive supranuclear palsy misdiagnosis
Correct Answer: A
A. Excessive dopaminergic medication causing mesolimbic pathway hyperactivity
[CORRECT]
Rationale: Dopaminergic medications (levodopa, dopamine agonists) can overstimulate
mesolimbic pathways, producing hallucinations and psychosis—distinguishable from
dementia with Lewy bodies hallucinations by temporal relationship to medication. B
describes DLB mechanism but not medication-induced. C causes delirium, not isolated
hallucinations. D is unrelated.
